Aigerim Murzakhmetova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aigerim Murzakhmetova has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Assel Meiramova
Astana Medical University
6 shared publications - Bayan Ainabekova
Department of Internal Medicine No. 2, Astana Medical University, 010000 Astana, Kazakhstan
4 shared publications - A. Ainabay
Astana Medical University NJSC 2. National Research Oncology Center
2 shared publications - Argul Issilbayeva
Laboratory of Microbiome, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
2 shared publications - B. Abdahina
Astana Medical University
2 shared publications - E. Omralina
“Astana Medical University” NCJSC
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Australasia Publishing Group in Central Asian Journal of Nephrology
- Vol. 2 (2, Suppl. ) , cajn_A11
Nephrology Registry as a Tool for Identification and Follow-Up of Patients with Chronic Kidney Disease
Introduction: Effective follow-up of patients with kidney disease requires systematic patient registration, monitoring of kidney function, assessment of disease progression risk, and timely referral. Proper organization of medical information and reducing the risk of human error are also important. There are no published data on a functioning chronic kidney disease registry at the primary health care level in Kazakhstan. This study presents the experience of implementing a nephrology registry in Viamedis LLP city polyclinics. Aim: To develop and implement a nephrology registry at the PHC level for data management, active identification of kidney function abnormalities, risk assessment, and improvement of patient follow-up. Materials and Methods: The registry was developed according to current regulations of the MHRK, including Order No. 149. It includes data from the population registered at four large city polyclinics of Viamedis LLP.The registry includes patients already under follow-up and patients actively identified based on available laboratory data. For patients with previous serum creatinine results, estimated glomerular filtration rate is automatically calculated using the CKD-EPI equation and classified according to eGFR categories.The registry also includes the 4-variable Kidney Failure Risk Equation to estimate the individual 2- and 5-year risk of kidney failure. Data on eGFR, urine albumin-to-creatinine ratio, medication availability, and sodium-glucose cotransporter-2 inhibitor therapy are also recorded. Results and Discussion: At the time of analysis, 3036 patients were under follow-up. During one month, the registry additionally identified 3051 patients outside the existing follow-up register based on previous serum creatinine results. 1462 patients (47,9%) had eGFR<60 ml. This shows a large potential for active identification of previously unregistered kidney function abnormalities and possible undiagnosed CKD requiring further confirmation and follow-up.KFRE-4 was used to assess the risk of kidney failure. Based on the 2-year risk calculation, 91 patients were identified, while 176 patients were identified using the 5-year risk calculation. These patients may require closer monitoring and timely referral to a nephrologist.The active identification results were obtained over one month. If these results are conditionally extrapolated to one year, the potential number of identified patients may increase substantially, highlighting the value of the registry as a tool for active kidney disease detection.The registry also included ACR results: 12861-A1, 1777-A2, and 67-A3 results. This allows albuminuria to be monitored over time and supports additional risk assessment.The integration of kidney function, ACR, laboratory monitoring, medication availability, and SGLT2 inhibitor therapy provided a more complete assessment of nephrology workload. Nephrology nurses supported data updating and patient follow-up, improving registry completeness. Conclusion: The nephrology registry at the PHC level allowed a shift from monitoring only known patients to active identification of previously unregistered kidney function abnormalities. Automated CKD-EPI calculation, ACR assessment, and KFRE-4 support risk stratification and timely referral. Integration of clinical, laboratory, and treatment data improves structured follow-up and provides a more objective assessment of nephrology workload. The registry provides a basis for a proactive approach to kidney disease management at the PHC level.
- 6 October 2026
- Published by Australasia Publishing Group in Central Asian Journal of Nephrology
- Vol. 2 (2, Suppl. ) , cajn_A11
Open AccessNephrology Registry as a Tool for Identification and Follow-Up of Patients with Chronic Kidney Disease
Introduction: Effective follow-up of patients with kidney disease requires systematic patient registration, monitoring of kidney function, assessment of disease progression risk, and timely referral. Proper organization of medical information and reducing the risk of human error are also important. There are no published data on a functioning chronic kidney disease registry at the primary health care level in Kazakhstan. This study presents the experience of implementing a nephrology registry in Viamedis LLP city polyclinics. Aim: To develop and implement a nephrology registry at the PHC level for data management, active identification of kidney function abnormalities, risk assessment, and improvement of patient follow-up. Materials and Methods: The registry was developed according to current regulations of the MHRK, including Order No. 149. It includes data from the population registered at four large city polyclinics of Viamedis LLP.The registry includes patients already under follow-up and patients actively identified based on available laboratory data. For patients with previous serum creatinine results, estimated glomerular filtration rate is automatically calculated using the CKD-EPI equation and classified according to eGFR categories.The registry also includes the 4-variable Kidney Failure Risk Equation to estimate the individual 2- and 5-year risk of kidney failure. Data on eGFR, urine albumin-to-creatinine ratio, medication availability, and sodium-glucose cotransporter-2 inhibitor therapy are also recorded. Results and Discussion: At the time of analysis, 3036 patients were under follow-up. During one month, the registry additionally identified 3051 patients outside the existing follow-up register based on previous serum creatinine results. 1462 patients (47,9%) had eGFR<60 ml. This shows a large potential for active identification of previously unregistered kidney function abnormalities and possible undiagnosed CKD requiring further confirmation and follow-up.KFRE-4 was used to assess the risk of kidney failure. Based on the 2-year risk calculation, 91 patients were identified, while 176 patients were identified using the 5-year risk calculation. These patients may require closer monitoring and timely referral to a nephrologist.The active identification results were obtained over one month. If these results are conditionally extrapolated to one year, the potential number of identified patients may increase substantially, highlighting the value of the registry as a tool for active kidney disease detection.The registry also included ACR results: 12861-A1, 1777-A2, and 67-A3 results. This allows albuminuria to be monitored over time and supports additional risk assessment.The integration of kidney function, ACR, laboratory monitoring, medication availability, and SGLT2 inhibitor therapy provided a more complete assessment of nephrology workload. Nephrology nurses supported data updating and patient follow-up, improving registry completeness. Conclusion: The nephrology registry at the PHC level allowed a shift from monitoring only known patients to active identification of previously unregistered kidney function abnormalities. Automated CKD-EPI calculation, ACR assessment, and KFRE-4 support risk stratification and timely referral. Integration of clinical, laboratory, and treatment data improves structured follow-up and provides a more objective assessment of nephrology workload. The registry provides a basis for a proactive approach to kidney disease management at the PHC level.
- 30 June 2026
- Published by Semey Medical University in Наука и здравоохранение
- No. 3(28),p. 71-79
SERUM AND URINARY BETA-2-MICROGLOBULIN IN PATIENTS WITH DIABETIC NEPHROPATHY: SIMILARITIES, DIFFERENCES AND DIAGNOSTIC VALUE
Introduction.Diabetic nephropathy is one of the most common and severe complications of type 2 diabetes mellitus and the leading cause of chronic kidney disease. Therefore, there is increasing interest in biomarkers, particularly tubular ones, reflecting early proximal tubule dysfunction. Aim. To summarize and quantify published data on serum and urinary beta-2-microglobulin levels in patients with diabetic nephropathy compared to control groups. Materials and methods. The meta-analysis included studies comparing serum or urinary beta-2-microglobulin levels in patients with diabetic nephropathy and control groups. All statistical analyses were performed using Review Manager (RevMan, version 5.4.1 (The Cochrane Collaboration, 2020). Results. In patients with diabetic nephropathy, beta-2-microglobulin levels were not statistically significantly higher than in control group patients, the pooled mean difference was MD=3.49; 95% CI from -0.16 to 7.14, p=0.06. A meta-analysis of the standardized mean difference in urinary beta-2-microglobulin levels showed that in patients with type 2 diabetes mellitus and diabetic nephropathy, urinary beta-2-microglobulin levels were 1.11 mg/ml higher compared to controls, 95% CI (0.32-1.91), p=0.006, and the standardized mean difference in the urinary beta-2-microglobulin to Creatinine levels increased by 1.07 mg/g in patients with type 2 diabetes mellitus and diabetic nephropathy compared to controls, 95% CI (0.04-2.11), p=0.04. Conclusions. The results of this meta-analysis allow us to summarize the results of studies of beta-2-microglobulin levels in patients with diabetic kidney disease. The level of this urinary biomarker and its ratio to creatinine were statistically significantly higher in patients with diabetic nephropathy compared to the control group. Введение. Диабетичесая нефропатия является одним из наиболее частых и тяжелых ослложнений сахарного диабета 2 типа и ведущей причиной хронической болезни почек. В связи с чем возрастает интерес к биомаркерам, в частности тубулярным, отражающим раннюю дисфункцию проксимальных канальцев. Цель. Обобщение и количественная оценка опубликованных данных о сывороточном и мочевом уровне бета-2-микроглобулина у пациентов с диабетической нефропатией по сравнению с контрольными группами. Материалы и методы. В метаанализ были включены исследования, сравнивающие уровни сывороточного или мочевого уровня бета-2-микроглобулина у пациентов с диабетической нефропатией и контрольных групп. Все статистические анализы проводились с использованием Review Manager (RevMan, версия 5.4.1 (The Cochrane Collaboration, 2020). Результаты. У пациентов с диабетической нефропатией уровень бета-2-микроглобулина не был статистически значимо выше, чем у пациентов групп контроля, объединённая разность средних значений составила MD=3,49; 95%ДИ от -0,16 до 7,14, р=0,06. %. Метаанализ стандартизированной разности средних значений уровня бета-2-микроглобулина в моче показал, что у пациентов с сахарным диабетом 2 типа с диабетический нефропатией уровень мочевого бета-2-микроглобулина был на 1,11 мг/мл выше по сравнению с контролем, 95% ДИ (0,32-1,91), р=0,006, и стандартизированная разность средних значений мочевого соотношения бета-2-микроглобулина к креатинину на 1,07 мг/г у пациентов с сахарным диабетом 2 типа с диабетической нефропатией в сравнении с контролем, 95% ДИ (0,04-2,11), р=0,04. Выводы. Результаты проведенного метаанализа позволяют нам обобщить результаты изучения уровня бета-2-микроглобулина у пациентов с диабетическим поражением почек. Уровень данного мочевого биомаркера и его соотношения к креатинину статистически значимо выше у пациентов с диабетической нефропатией в сравнении с группой контроля. Кіріспе. Диабеттік нефропатия 2 типті қант диабетінің ең көп таралған және ауыр асқынуларының бірі және созылмалы бүйрек ауруының негізгі себебі болып табылады. Сондықтан, проксимальды түтікшелердің ерте дисфункциясын көрсететін биомаркерлерге, әсіресе түтікшелерге қызығушылық артып келеді. Мақсаты. Бақылау топтарымен салыстырғанда диабеттік нефропатиясы бар науқастардағы сарысу мен зәрдегі бета-2-микроглобулин...
- 30 June 2026
- Published by Semey Medical University in Наука и здравоохранение
- No. 3(28),p. 71-79
SERUM AND URINARY BETA-2-MICROGLOBULIN IN PATIENTS WITH DIABETIC NEPHROPATHY: SIMILARITIES, DIFFERENCES AND DIAGNOSTIC VALUE
Introduction.Diabetic nephropathy is one of the most common and severe complications of type 2 diabetes mellitus and the leading cause of chronic kidney disease. Therefore, there is increasing interest in biomarkers, particularly tubular ones, reflecting early proximal tubule dysfunction. Aim. To summarize and quantify published data on serum and urinary beta-2-microglobulin levels in patients with diabetic nephropathy compared to control groups. Materials and methods. The meta-analysis included studies comparing serum or urinary beta-2-microglobulin levels in patients with diabetic nephropathy and control groups. All statistical analyses were performed using Review Manager (RevMan, version 5.4.1 (The Cochrane Collaboration, 2020). Results. In patients with diabetic nephropathy, beta-2-microglobulin levels were not statistically significantly higher than in control group patients, the pooled mean difference was MD=3.49; 95% CI from -0.16 to 7.14, p=0.06. A meta-analysis of the standardized mean difference in urinary beta-2-microglobulin levels showed that in patients with type 2 diabetes mellitus and diabetic nephropathy, urinary beta-2-microglobulin levels were 1.11 mg/ml higher compared to controls, 95% CI (0.32-1.91), p=0.006, and the standardized mean difference in the urinary beta-2-microglobulin to Creatinine levels increased by 1.07 mg/g in patients with type 2 diabetes mellitus and diabetic nephropathy compared to controls, 95% CI (0.04-2.11), p=0.04. Conclusions. The results of this meta-analysis allow us to summarize the results of studies of beta-2-microglobulin levels in patients with diabetic kidney disease. The level of this urinary biomarker and its ratio to creatinine were statistically significantly higher in patients with diabetic nephropathy compared to the control group. Введение. Диабетичесая нефропатия является одним из наиболее частых и тяжелых ослложнений сахарного диабета 2 типа и ведущей причиной хронической болезни почек. В связи с чем возрастает интерес к биомаркерам, в частности тубулярным, отражающим раннюю дисфункцию проксимальных канальцев. Цель. Обобщение и количественная оценка опубликованных данных о сывороточном и мочевом уровне бета-2-микроглобулина у пациентов с диабетической нефропатией по сравнению с контрольными группами. Материалы и методы. В метаанализ были включены исследования, сравнивающие уровни сывороточного или мочевого уровня бета-2-микроглобулина у пациентов с диабетической нефропатией и контрольных групп. Все статистические анализы проводились с использованием Review Manager (RevMan, версия 5.4.1 (The Cochrane Collaboration, 2020). Результаты. У пациентов с диабетической нефропатией уровень бета-2-микроглобулина не был статистически значимо выше, чем у пациентов групп контроля, объединённая разность средних значений составила MD=3,49; 95%ДИ от -0,16 до 7,14, р=0,06. %. Метаанализ стандартизированной разности средних значений уровня бета-2-микроглобулина в моче показал, что у пациентов с сахарным диабетом 2 типа с диабетический нефропатией уровень мочевого бета-2-микроглобулина был на 1,11 мг/мл выше по сравнению с контролем, 95% ДИ (0,32-1,91), р=0,006, и стандартизированная разность средних значений мочевого соотношения бета-2-микроглобулина к креатинину на 1,07 мг/г у пациентов с сахарным диабетом 2 типа с диабетической нефропатией в сравнении с контролем, 95% ДИ (0,04-2,11), р=0,04. Выводы. Результаты проведенного метаанализа позволяют нам обобщить результаты изучения уровня бета-2-микроглобулина у пациентов с диабетическим поражением почек. Уровень данного мочевого биомаркера и его соотношения к креатинину статистически значимо выше у пациентов с диабетической нефропатией в сравнении с группой контроля. Кіріспе. Диабеттік нефропатия 2 типті қант диабетінің ең көп таралған және ауыр асқынуларының бірі және созылмалы бүйрек ауруының негізгі себебі болып табылады. Сондықтан, проксимальды түтікшелердің ерте дисфункциясын көрсететін биомаркерлерге, әсіресе түтікшелерге қызығушылық артып келеді. Мақсаты. Бақылау топтарымен салыстырғанда диабеттік нефропатиясы бар науқастардағы сарысу мен зәрдегі бета-2-микроглобулин...
- 31 March 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 67 (1)
EVALUATION OF KIDNEY FUNCTION IN AN ELDERLY PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
Relevance: Kidney functions in treating acute myeloblastic leukemia (AML) undergo serious effects, especially in elderly patients. Chemotherapeutic drugs used to prepare for hematopoietic stem cell transplantation (HSCT) inevitably affect elderly patients’ kidney function. Moreover, involutive changes in the kidneys can physiologically decrease kidney function. The study aimed to evaluate kidney function in an elderly patient with AML after HSCT. Methods: The article describes a clinical case of AML in an elderly patient who underwent allogeneic HSCT. Results: We analyzed the dynamics of the functional state from the moment of registration of AML to +100 days after HSCT. During the entire follow-up period, we did not detect any renal dysfunction in the elderly patient. Despite the HSCT and the effects of nephrotoxic drugs in an elderly patient + 100 days after HSCT, kidney function was preserved. Conclusion: The described case highlights the importance of maintaining renal function in elderly patients after HSCT and long-term renal monitoring.
- 31 March 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 67 (1)
EVALUATION OF KIDNEY FUNCTION IN AN ELDERLY PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
Relevance: Kidney functions in treating acute myeloblastic leukemia (AML) undergo serious effects, especially in elderly patients. Chemotherapeutic drugs used to prepare for hematopoietic stem cell transplantation (HSCT) inevitably affect elderly patients’ kidney function. Moreover, involutive changes in the kidneys can physiologically decrease kidney function. The study aimed to evaluate kidney function in an elderly patient with AML after HSCT. Methods: The article describes a clinical case of AML in an elderly patient who underwent allogeneic HSCT. Results: We analyzed the dynamics of the functional state from the moment of registration of AML to +100 days after HSCT. During the entire follow-up period, we did not detect any renal dysfunction in the elderly patient. Despite the HSCT and the effects of nephrotoxic drugs in an elderly patient + 100 days after HSCT, kidney function was preserved. Conclusion: The described case highlights the importance of maintaining renal function in elderly patients after HSCT and long-term renal monitoring.
- 31 March 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 67 (1)
EVALUATION OF KIDNEY FUNCTION IN AN ELDERLY PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
Relevance: Kidney functions in treating acute myeloblastic leukemia (AML) undergo serious effects, especially in elderly patients. Chemotherapeutic drugs used to prepare for hematopoietic stem cell transplantation (HSCT) inevitably affect elderly patients’ kidney function. Moreover, involutive changes in the kidneys can physiologically decrease kidney function. The study aimed to evaluate kidney function in an elderly patient with AML after HSCT. Methods: The article describes a clinical case of AML in an elderly patient who underwent allogeneic HSCT. Results: We analyzed the dynamics of the functional state from the moment of registration of AML to +100 days after HSCT. During the entire follow-up period, we did not detect any renal dysfunction in the elderly patient. Despite the HSCT and the effects of nephrotoxic drugs in an elderly patient + 100 days after HSCT, kidney function was preserved. Conclusion: The described case highlights the importance of maintaining renal function in elderly patients after HSCT and long-term renal monitoring.
- 31 March 2023
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 67 (1)
EVALUATION OF KIDNEY FUNCTION IN AN ELDERLY PATIENT WITH ACUTE MYELOBLASTIC LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A CASE REPORT
Relevance: Kidney functions in treating acute myeloblastic leukemia (AML) undergo serious effects, especially in elderly patients. Chemotherapeutic drugs used to prepare for hematopoietic stem cell transplantation (HSCT) inevitably affect elderly patients’ kidney function. Moreover, involutive changes in the kidneys can physiologically decrease kidney function. The study aimed to evaluate kidney function in an elderly patient with AML after HSCT. Methods: The article describes a clinical case of AML in an elderly patient who underwent allogeneic HSCT. Results: We analyzed the dynamics of the functional state from the moment of registration of AML to +100 days after HSCT. During the entire follow-up period, we did not detect any renal dysfunction in the elderly patient. Despite the HSCT and the effects of nephrotoxic drugs in an elderly patient + 100 days after HSCT, kidney function was preserved. Conclusion: The described case highlights the importance of maintaining renal function in elderly patients after HSCT and long-term renal monitoring.
- Open Access
- 16 February 2023
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 17 (1)
Association of β2 microglobulin level and glomerular filtration rate in patients with acute leukemia after hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation is a life-saving therapy in patients suffering from acute leukemia. However, kidney complications developed after performing hematopoietic stem cell transplantation can affect the course and prognosis of the disease in patients with acute leukemia. This study is aimed at assessing the functional status of the kidneys in patients with acute leukemia who have undergone hematopoietic stem cell transplantation. The study has observed a group of patients with acute lymphoblastic leukemia and acute myeloid leukemia who have undergone hematopoietic stem cell transplantation. It has been discovered that β2 microglobulin is a sensitive method of analyzing renal function, with the β2 microglobulin threshold urine level not exceeding 0.3 mg/L. The complex diagnostics of kidney function in hematopoietic stem cell transplantation recipients has given the opportunity to identify the relationship between increased β2 microglobulin levels and decreased glomerular filtration rate. It has been determined that β2 microglobulin is a biomarker of renal disorders. The obtained data have showed that β2 microglobulin can be used as a diagnostic marker of reduced kidney function.
- 16 February 2023
- Published by PAGEPress Publications in Italian Journal of Medicine
- Vol. 17 (1)
Open AccessAssociation of β2 microglobulin level and glomerular filtration rate in patients with acute leukemia after hematopoietic stem cell transplantation
Hematopoietic stem cell transplantation is a life-saving therapy in patients suffering from acute leukemia. However, kidney complications developed after performing hematopoietic stem cell transplantation can affect the course and prognosis of the disease in patients with acute leukemia. This study is aimed at assessing the functional status of the kidneys in patients with acute leukemia who have undergone hematopoietic stem cell transplantation. The study has observed a group of patients with acute lymphoblastic leukemia and acute myeloid leukemia who have undergone hematopoietic stem cell transplantation. It has been discovered that β2 microglobulin is a sensitive method of analyzing renal function, with the β2 microglobulin threshold urine level not exceeding 0.3 mg/L. The complex diagnostics of kidney function in hematopoietic stem cell transplantation recipients has given the opportunity to identify the relationship between increased β2 microglobulin levels and decreased glomerular filtration rate. It has been determined that β2 microglobulin is a biomarker of renal disorders. The obtained data have showed that β2 microglobulin can be used as a diagnostic marker of reduced kidney function.
- 30 September 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 65 (3)
ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SERIES OF CLINICAL CASES
Relevance: Acute renal kidney injury is a severe complication in patients with acute leukemia who underwent hematopoietic stem cell transplantation (HSCT). According to statistics, acute renal dysfunction often occurs in the first 100 days after HSCT. This study aimed to evaluate kidney function in patients with acute leukemia after hematopoietic stem cell transplantation. Methods: The article presents clinical cases of patients with acute lymphoblastic leukemia who developed acute renal failure after HSCT. The dynamics of the functional state of kidneys in patients with acute lymphoblastic leukemia after HSCT are described. Results: The acute kidney disorder in the studied patients was mainly caused by HSCT complications. We have identified renal kidney damage in the form of acute tumor lysis and thrombotic microangiopathy. Conclusion: Patients with acute lymphoblastic leukemia risk developing acute kidney disorder during HSCT, which requires careful monitoring of kidney function, especially in the early post-transplant period
- 30 September 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 65 (3)
ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SERIES OF CLINICAL CASES
Relevance: Acute renal kidney injury is a severe complication in patients with acute leukemia who underwent hematopoietic stem cell transplantation (HSCT). According to statistics, acute renal dysfunction often occurs in the first 100 days after HSCT. This study aimed to evaluate kidney function in patients with acute leukemia after hematopoietic stem cell transplantation. Methods: The article presents clinical cases of patients with acute lymphoblastic leukemia who developed acute renal failure after HSCT. The dynamics of the functional state of kidneys in patients with acute lymphoblastic leukemia after HSCT are described. Results: The acute kidney disorder in the studied patients was mainly caused by HSCT complications. We have identified renal kidney damage in the form of acute tumor lysis and thrombotic microangiopathy. Conclusion: Patients with acute lymphoblastic leukemia risk developing acute kidney disorder during HSCT, which requires careful monitoring of kidney function, especially in the early post-transplant period
- 30 September 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 65 (3)
ACUTE RENAL DISORDER IN PATIENTS WITH ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SERIES OF CLINICAL CASES
Relevance: Acute renal kidney disorder is a serious complication in patients with acute leukemia who underwent hematopoietic stem cell transplantation (HSCT). According to statistics, acute renal dysfunction often occurs in the first 100 days after HSCT. This study aimed to evaluate kidney function in patients with acute leukemia after hematopoietic stem cell transplantation. Methods: The article presents clinical cases of patients with acute lymphoblastic leukemia who developed acute renal failure after HSCT. The dynamics of the functional state of kidneys in patients with acute lymphoblastic leukemia after HSCT are described. Results: The acute kidney disorder in the studied patients was mainly caused by HSCT complications. We have identified renal kidney damage in the form of acute tumor lysis and thrombotic microangiopathy. Conclusion: Patients with acute lymphoblastic leukemia risk developing acute kidney disorder during HSCT, which requires careful monitoring of kidney function, especially in the early post-transplant period.
- 30 September 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 65 (3)
ACUTE RENAL DISORDER IN PATIENTS WITH ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SERIES OF CLINICAL CASES
Relevance: Acute renal kidney disorder is a serious complication in patients with acute leukemia who underwent hematopoietic stem cell transplantation (HSCT). According to statistics, acute renal dysfunction often occurs in the first 100 days after HSCT. This study aimed to evaluate kidney function in patients with acute leukemia after hematopoietic stem cell transplantation. Methods: The article presents clinical cases of patients with acute lymphoblastic leukemia who developed acute renal failure after HSCT. The dynamics of the functional state of kidneys in patients with acute lymphoblastic leukemia after HSCT are described. Results: The acute kidney disorder in the studied patients was mainly caused by HSCT complications. We have identified renal kidney damage in the form of acute tumor lysis and thrombotic microangiopathy. Conclusion: Patients with acute lymphoblastic leukemia risk developing acute kidney disorder during HSCT, which requires careful monitoring of kidney function, especially in the early post-transplant period.
- Open Access
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (B) , 937-943
Evaluation of Kidneys’ Functional State in Acute Lymphoblastic Leukemia Patients Following Hematopoietic Stem Cell Transplantation
BACKGROUND: Hematopoietic Stem Cell Transplantation (HSCT) has recently been a widely used method of therapy in various fields of current medicine, particularly in hematology.Some patients develop renal disorders following HSCT. AIM: This study aims to evaluate the dynamics of changes in the functional state of the kidneys in patients with ALL after HSCT. METHODS: In the period from 2015 to 2021, for the first time in Kazakhstan, patients with acute lymphoblastic leukemia (ALL) who underwent allogeneic and haploidentical HSCT were prospectively examined. RESULTS: We determined that the greatest decrease in glomerular filtration rate occurred in the group of patients who underwent haploidentical bone marrow transplantation. Moreover, we believe that our results are related to known contributing risk factors, such as the type of performed transplantation and the duration of taking medications for the prevention of graft versus host disease. Our results also indicate that the lethal outcome in the group with haploidentical HSCT in the studied patients with ALL was greater than in the group with allogeneic HSCT. CONCLUSION: In conclusion, a decrease in kidney function in patients who have survived HSCT is probably a common complication; however, further prospective studies are required to confirm these results to develop additional algorithms for the treatment and prevention of renal disorders in patients with acute leukemia after HSCT.
- 1 January 2022
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 10 (B) , 937-943
Open AccessEvaluation of Kidneys’ Functional State in Acute Lymphoblastic Leukemia Patients Following Hematopoietic Stem Cell Transplantation
BACKGROUND: Hematopoietic Stem Cell Transplantation (HSCT) has recently been a widely used method of therapy in various fields of current medicine, particularly in hematology.Some patients develop renal disorders following HSCT. AIM: This study aims to evaluate the dynamics of changes in the functional state of the kidneys in patients with ALL after HSCT. METHODS: In the period from 2015 to 2021, for the first time in Kazakhstan, patients with acute lymphoblastic leukemia (ALL) who underwent allogeneic and haploidentical HSCT were prospectively examined. RESULTS: We determined that the greatest decrease in glomerular filtration rate occurred in the group of patients who underwent haploidentical bone marrow transplantation. Moreover, we believe that our results are related to known contributing risk factors, such as the type of performed transplantation and the duration of taking medications for the prevention of graft versus host disease. Our results also indicate that the lethal outcome in the group with haploidentical HSCT in the studied patients with ALL was greater than in the group with allogeneic HSCT. CONCLUSION: In conclusion, a decrease in kidney function in patients who have survived HSCT is probably a common complication; however, further prospective studies are required to confirm these results to develop additional algorithms for the treatment and prevention of renal disorders in patients with acute leukemia after HSCT.